1560 TRAPELO ROAD, WALTHAM, MA
Barry E. Greene Elected as Class I Director at Dyne Therapeutics
Material disclosure
Dyne Therapeutics Elects Directors at 2026 Annual Meeting
Announces Completion of Enrollment in Registrational Expansion Cohort of ACHIEVE Trial of Z-Basivarsen for Myotonic Dystrophy Type 1 (DM1)
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Annual Report to Security Holders
Financial Results, Press Release
Investor Presentation
Q1
FY 2025
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities